Effect of systemic oxytocin administration on dexamethasone-induced leptin secretion in normal and obese men. 2000

P Chiodera, and R Volpi, and L Capretti, and S Cataldo, and G Speroni, and V Coiro
Dipartimento di Medicina Interna e Scienze Biomediche, Facoltà di Medicina, Università di Parma Italy.

To establish whether the regulatory mechanism of leptin secretion is sensitive to oxytocin (OT), seven healthy nonobese men were tested with dexamethasone (dex; 4 mg, iv, at 0730 h) in feeding (2000 Cal given at 3 meals over 7 h) conditions either in the absence (iv normal saline infusion) or in the presence of a constant iv infusion of OT (1, 2, or 4 mIU/min from 0730 h for 10 h). In six additional subjects under similar experimental conditions, normal saline or OT (1, 2, or 4 mIU/min from 0730 h for 10 h) were infused iv without the previous treatment with dexamethasone. Serum leptin concentrations were measured in samples taken at 60-min intervals during infusion. Leptin levels remained constant during the infusion of normal saline or OT (1, 2, or 4 mIU/min) alone. In contrast, serum leptin concentrations rose significantly from the baseline after dex administration. The leptin response to dex was not modified by the concomitant infusion of 1 mIU/min OT, whereas it was completely abolished by the administration of 2 or 4 mIU/min OT. These findings led us to evaluate the secretory pattern of leptin in 12 obese patients in similar experimental conditions. In all patients basal leptin levels were significantly higher than those in normal weight subjects. In 6 obese subjects, the infusion of OT alone (1, 2, or 4 mIU/min) was unable to change serum leptin levels. In the remaining 6 obese subjects, dex administration significantly increased serum leptin levels; however, the leptin response to dex was not modified by the concomitant infusion of 1, 2, or 4 mIU/min OT. These data show inhibition by elevated circulating OT levels of glucocorticoid-induced, but not basal, leptin secretion in normal weight subjects, suggesting a possible role for OT in the regulatory control of leptin. Furthermore, the results obtained in obese subjects indicate that this regulation is disrupted in obesity.

UI MeSH Term Description Entries
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D009765 Obesity A status with BODY WEIGHT that is grossly above the recommended standards, usually due to accumulation of excess FATS in the body. The standards may vary with age, sex, genetic or cultural background. In the BODY MASS INDEX, a BMI greater than 30.0 kg/m2 is considered obese, and a BMI greater than 40.0 kg/m2 is considered morbidly obese (MORBID OBESITY).
D010121 Oxytocin A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION. Ocytocin,Pitocin,Syntocinon
D003907 Dexamethasone An anti-inflammatory 9-fluoro-glucocorticoid. Hexadecadrol,Decaject,Decaject-L.A.,Decameth,Decaspray,Dexasone,Dexpak,Hexadrol,Maxidex,Methylfluorprednisolone,Millicorten,Oradexon,Decaject L.A.
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D020738 Leptin A 16-kDa peptide hormone secreted from WHITE ADIPOCYTES. Leptin serves as a feedback signal from fat cells to the CENTRAL NERVOUS SYSTEM in regulation of food intake, energy balance, and fat storage. Ob Protein,Obese Protein,Ob Gene Product,Obese Gene Product,Gene Product, Ob,Gene Product, Obese

Related Publications

P Chiodera, and R Volpi, and L Capretti, and S Cataldo, and G Speroni, and V Coiro
October 2017, Acta clinica Belgica,
P Chiodera, and R Volpi, and L Capretti, and S Cataldo, and G Speroni, and V Coiro
June 2002, Neuro endocrinology letters,
P Chiodera, and R Volpi, and L Capretti, and S Cataldo, and G Speroni, and V Coiro
December 2018, International journal of molecular sciences,
P Chiodera, and R Volpi, and L Capretti, and S Cataldo, and G Speroni, and V Coiro
May 2000, Revista medica de Chile,
P Chiodera, and R Volpi, and L Capretti, and S Cataldo, and G Speroni, and V Coiro
September 1993, Journal of endocrinological investigation,
P Chiodera, and R Volpi, and L Capretti, and S Cataldo, and G Speroni, and V Coiro
October 2009, The Journal of endocrinology,
P Chiodera, and R Volpi, and L Capretti, and S Cataldo, and G Speroni, and V Coiro
February 2003, Journal of endocrinological investigation,
P Chiodera, and R Volpi, and L Capretti, and S Cataldo, and G Speroni, and V Coiro
January 1982, Journal of neural transmission,
P Chiodera, and R Volpi, and L Capretti, and S Cataldo, and G Speroni, and V Coiro
January 1986, Psychoneuroendocrinology,
P Chiodera, and R Volpi, and L Capretti, and S Cataldo, and G Speroni, and V Coiro
February 1991, Revista clinica espanola,
Copied contents to your clipboard!